Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × lanreotide × Endocrine × Clear all

Phase

Status

Completed 7 Unknown 4 Recruiting 4 Terminated 3 Withdrawn 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Serotonin Syndrome 1 Carcinoid Heart Disease 1

Interventions

telotristat ethyl 4 lutetium Lu 177 dotatate 3 gallium Ga 68 dotatate 2 Temozolomide 2 Octreotide 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 veliparib 1 vatalanib 1 vandetanib 1 trametinib 1 pembrolizumab 1 pasireotide 1 lanreotide 1 fosbretabulin 1 dabrafenib 1 combretastatin 1 ceritinib 1 Tretinoin 1 Panitumumab 1 Paclitaxel 1 Microarray Analysis 1 Isotretinoin 1 Introns 1 Everolimus 1 Docetaxel 1 Diazoxide 1 DNA Methylation 1 Carboplatin 1 Capecitabine 1 Biological Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡